Clinical Trial

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-01-25; most recent amendment 2025-12-18.
Status change: Not Yet Recruiting → Recruiting 2024-02-15
Trial Details
NCT Number NCT06239116
Lead Sponsor Rhythm Pharmaceuticals, Inc.
Conditions Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Enrollment 150 participants
Start Date 2024-03-05
Primary Completion 2027-11-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-22